赤红补肺胶囊辅助治疗对慢性肺源性心脏病患者肺动脉高压及肺功能的影响  

Effects of Chihong Bufei capsule on treating pulmonary artery hypertension and pulmonary function in patients with chronic cardiopulmonary disease

作　　者：俞静[1] 杨思进[1] 白雪[1] 罗永兵[1] 周钰[2] 

机构地区：[1]泸州医学院附属中医院,四川泸州646000 [2]新疆医科大学第一附属医院,新疆乌鲁木齐646000

出　　处：《中医临床研究》2014年第35期16-18,共3页Clinical Journal Of Chinese Medicine

基　　金：四川省泸州市科技局课题[2013-S-47(11/20)];新疆名医名方与特色方剂学实验室开放基金(XJDX0910-2013-03)

摘　　要：目的:探讨赤红补肺胶囊用于慢性肺源性心脏病(肺心病)肺动脉高压及肺功能疗效。方法:将80例慢性肺心病缓解期患者随机分为对照组40例和治疗组40例,对照组和治疗组均接受常规治疗,治疗组在此基础上加用赤红补肺胶囊,连续6周。治疗组及对照组分别于治疗前及治疗后6个月检测下列指标:肺功能、肺动脉压(PAP)及血浆高敏-C反应蛋白(hs-CRP)、IL-8水平。结果:治疗组和对照组治疗前肺功能指标及PAP、hs.CRP、IL-8无统计学差异(P>0.05),治疗后治疗组和对照组FEVl、FEVl/FVC等肺功能指标明显升高(P<0.05),PAP、hs-CRP、IL-8均较同组治疗前和对照组明显降低(P<0.05);但治疗组治疗前后FEVl、FEVl/FVC、PAP、hs-CRP和IL-8的差值明显高于对照组治疗前后差值(P<0.05);治疗组口服赤红补肺胶囊期间3例出现AST升高2.0倍,2例出现肌酸激酶升高3.0倍,停药后均恢复正常。结论:赤红补肺胶囊可辅助西医常规治疗方案改善慢性肺心脏病患者的肺功能、降低PAP,机制可能与抑制肺血管炎性反应有关。Objective： To explore effects and mechanism of Chihong Bufei capsule as a adjunctive therapy on treating pulmonary artery hypertension and pulmonary function in patients with chronic cardiopulmonary disease. Methods： Total of 80 patients with chronic pulmonary heart disease in stable period were randomly divided into the control group （n=40） and the treatment group （n=40）. Patients in two groups were given routine treatment and the treatment group was given Chihong Bufei capsule for 6 weeks. Changes in pulmonary function, pulmonary arterial pressure （PAP）, hs-CRP and IL-8 in the control group and the treatment group were observed before and after 6 months of treatment. Results： The pulmonary function indexes, pulmonary arterial pressure （PAP） and levels of hs-CRP, IL-8 in the control group and treatment group before treatment showed no significant difference （P〉0.05）, but were all significantly higher than those in the healthy control group （P〈0.05）; the pulmonary function indexes including FEV1 and FEV1/FVC were much better in the treatment group after treatment （P〈0.05）, while the PAP, hs-CRP and IL-8 decreased after 6 months （P〈0.05）, the change of FEV1, FEV1/FVC, PAP, hs-CRP and IL-8 between before and after treatment in treatment group was larger than the control group. The AST of 3 patient increased 2.0 fold. myalgia and increased creatine kinase of 3.0 fold were found in another two patients. The above clinical indexes returned to normal after the stopping of atorvastatin. Conclusion： Chihong Bufei capsule as a adjunctive therapy can help western medicine treatment effectively improve the pulmonary function, decrease PAP of patients with chronic pulmonary heart disease. These effects may be related to the increase of the number and functions of EPCs induced by the inhibition of inflammation in pulmonary vessels.

关 键 词：赤红补肺胶囊 肺源性心脏病 肺动脉高压 高敏-C反应蛋白 

分 类 号：R541.5[医药卫生—心血管疾病]